Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1986 2
1987 2
1989 2
1990 1
1991 3
1992 2
1993 1
1994 2
1995 2
1996 3
1997 3
1998 3
1999 3
2000 5
2001 1
2002 3
2003 2
2005 1
2006 2
2007 1
2008 5
2009 5
2010 4
2011 5
2012 4
2013 4
2014 8
2015 10
2016 6
2017 3
2018 5
2019 3
2020 4
2021 3
2022 8
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Severe Aplastic Anemia"
Page 1
Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment.
Georges GE, Doney K, Storb R. Georges GE, et al. Blood Adv. 2018 Aug 14;2(15):2020-2028. doi: 10.1182/bloodadvances.2018021162. Blood Adv. 2018. PMID: 30108110 Free PMC article. Review.
Treatment of severe aplastic anemia has improved significantly over the past 4 decades. ...Implementation of this first-line treatment strategy will provide patients with severe aplastic anemia the best chance of long-term disease-free su …
Treatment of severe aplastic anemia has improved significantly over the past 4 decades. ...Implementation of this first …
Immunosuppressive therapy in severe aplastic anemia.
Patel BA, Townsley DM, Scheinberg P. Patel BA, et al. Semin Hematol. 2022 Jan;59(1):21-29. doi: 10.1053/j.seminhematol.2022.01.002. Epub 2022 Jan 19. Semin Hematol. 2022. PMID: 35491055
Severe aplastic anemia, a disease characterized by pancytopenia and a hypocellular marrow, is treatable by either immunosuppressive therapy (IST) or hematopoietic stem cell transplant. ...
Severe aplastic anemia, a disease characterized by pancytopenia and a hypocellular marrow, is treatable by either immun …
Temozolomide-related hematologic toxicity.
Scaringi C, De Sanctis V, Minniti G, Enrici RM. Scaringi C, et al. Onkologie. 2013;36(7-8):444-9. doi: 10.1159/000353752. Epub 2013 Jul 8. Onkologie. 2013. PMID: 23921765 Review.
Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with significant survival benefit. ...The most common side effects are mild to moderate, and are represented by fatigue, nausea, vomiting, thrombocytopen …
Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with signific …
Eltrombopag in aplastic anemia.
Desmond R, Townsley DM, Dunbar C, Young NS. Desmond R, et al. Semin Hematol. 2015 Jan;52(1):31-7. doi: 10.1053/j.seminhematol.2014.10.002. Epub 2014 Oct 31. Semin Hematol. 2015. PMID: 25578417 Free PMC article. Review.
The treatment of aplastic anemia is currently with immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and cyclosporine, to which two thirds of patients respond. ...A recent trial has shown that eltrombopag, a thrombopoeitin mimetic, is efficacious in …
The treatment of aplastic anemia is currently with immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and cycl …
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.
DeZern AE, Eapen M, Wu J, Talano JA, Solh M, Dávila Saldaña BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Brodsky RA, Logan BR, Horowitz MM, Jones RJ, Pulsipher MA. DeZern AE, et al. Lancet Haematol. 2022 Sep;9(9):e660-e669. doi: 10.1016/S2352-3026(22)00206-X. Epub 2022 Jul 27. Lancet Haematol. 2022. PMID: 35907408 Free PMC article. Clinical Trial.
BACKGROUND: Relapsed severe aplastic anaemia is a marrow failure disorder with high morbidity and mortality. ...This study aimed to understand the 1-year overall survival in patients with relapsed or refractory severe aplastic anaemia aft …
BACKGROUND: Relapsed severe aplastic anaemia is a marrow failure disorder with high morbidity and mortality. ...This st …
Anti-thymocyte globulin in haematology: Recent developments.
Siddiqui S, Cox J, Herzig R, Palaniyandi S, Hildebrandt GC, Munker R. Siddiqui S, et al. Indian J Med Res. 2019 Sep;150(3):221-227. doi: 10.4103/ijmr.IJMR_752_19. Indian J Med Res. 2019. PMID: 31719292 Free PMC article. Review.
It induces a broad non-specific immunosuppression. In haematology, standard indications are severe aplastic anaemia and prophylaxis and treatment of graft-versus-host disease (GVHD) (after allogeneic transplantation). For aplastic anaemia, ATG f …
It induces a broad non-specific immunosuppression. In haematology, standard indications are severe aplastic anaemia and …
Acquired aplastic anemia following SARS-CoV-2 vaccination.
Röth A, Bertram S, Schroeder T, Haverkamp T, Voigt S, Holtkamp C, Klump H, Wörmann B, Reinhardt HC, Alashkar F. Röth A, et al. Eur J Haematol. 2022 Aug;109(2):186-194. doi: 10.1111/ejh.13788. Epub 2022 Jun 1. Eur J Haematol. 2022. PMID: 35592930 Free PMC article.
COVID-19 is a potential life-threatening viral disease caused by SARS-CoV-2 and was declared a pandemic by the WHO in March 2020. mRNA-based SARS-CoV-2 vaccines are routinely recommended in immune-compromised patients, including patients with AA, as these patients are at increase …
COVID-19 is a potential life-threatening viral disease caused by SARS-CoV-2 and was declared a pandemic by the WHO in March 2020. mRNA-based …
Neonatal manifestations of inherited bone marrow failure syndromes.
Khincha PP, Savage SA. Khincha PP, et al. Semin Fetal Neonatal Med. 2016 Feb;21(1):57-65. doi: 10.1016/j.siny.2015.12.003. Epub 2015 Dec 24. Semin Fetal Neonatal Med. 2016. PMID: 26724991 Free PMC article. Review.
The inherited bone marrow failure syndromes (IBMFS) are a rare yet clinically important cause of neonatal hematological and non-hematological manifestations. Many of these syndromes, such as Fanconi anemia, dyskeratosis congenita and Diamond-Blackfan anemia, confer …
The inherited bone marrow failure syndromes (IBMFS) are a rare yet clinically important cause of neonatal hematological and non-hematologica …
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study.
Aggarwal N, Manley AL, Shalhoub R, Durrani J, Rios O, Lotter J, Patel BA, Wu CO, Young NS, Groarke EM. Aggarwal N, et al. Am J Hematol. 2023 Jun;98(6):932-939. doi: 10.1002/ajh.26924. Epub 2023 Apr 6. Am J Hematol. 2023. PMID: 37021397 Free PMC article. Clinical Trial.
Immune severe aplastic anemia (SAA) is characterized by pancytopenia and immune-mediated bone marrow destruction. ...
Immune severe aplastic anemia (SAA) is characterized by pancytopenia and immune-mediated bone marrow destruction. ...
A New Immunosuppressive Therapy for Very Severe Aplastic Anemia in Children with Autoantibodies.
Wang ZJ, Chen HB, Zhou F, Yu H, Wu XY, Shen YQ, Qiu YN, Jin RM. Wang ZJ, et al. Curr Med Sci. 2022 Apr;42(2):379-386. doi: 10.1007/s11596-022-2519-2. Epub 2022 Mar 8. Curr Med Sci. 2022. PMID: 35258748
OBJECTIVE: At present, a number of very severe aplastic anemia (VSAA) patients cannot receive hematopoietic stem cell transplantation (HSCT) or standard immunosuppressive therapy (IST) due to the high cost of therapy, shortage of sibling donors, and lack of r …
OBJECTIVE: At present, a number of very severe aplastic anemia (VSAA) patients cannot receive hematopoietic stem cell t …
114 results